ImmunityBio is a San Diego-based clinical stage immunotherapy company with 628 employees, focusing on therapies for urologic cancers and infectious diseases. Its lead product candidate, Anktiva, is an IL-15 superagonist fusion protein.
IBRX filed a patent for "generation of chimeric antigen receptor mrna molecules for expression in primary nk cells" on Wed, January 17, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
